肝细胞癌
去唾液酸糖蛋白受体
医学
肝癌
药品
纳米载体
靶向给药
癌症
药物输送
癌症研究
靶向治疗
药理学
内科学
化学
体外
肝细胞
有机化学
生物化学
作者
Sudhanshu Mishra,Amrita Singh,Saurabh Sharma,Smriti Ojha,S Bhalodia Yagnik,Sudhi Pandey
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2023-12-01
卷期号:23 (11): 879-888
标识
DOI:10.2174/1568009623666230503094346
摘要
One of the most important health problems in the world today is cancer. The World Health Organization (WHO) reported that it results in 8.9 million deaths annually. Malignant tumours and unregulated cell proliferation are features of malignant neoplasms, which can also invade nearby body regions. Hepatocellular carcinoma is the third most prevalent cause of cancer-related death worldwide and the fifth most common kind of cancer, according to a recent analysis. Patients with liver disease as well as chronic hepatitis B and C are more likely to develop hepatocellular carcinoma (HCC). Physical barriers, including RES absorption, opsonization, and first-pass drug metabolism, make drug therapy more challenging. Conventional cancer therapy procedures have a low response rate or may continue to be unsuccessful due to multi-drug resistance (MDR), high clearance rates, and other side effects because of suboptimal drug distribution and insufficient drug concentration reaching cancer cells. Innovative target drug molecules that are tailored to the injured liver cells must be developed in order to improve medication administration and drug targeting. The use of targeting ligands that have been joined to drug molecules or nanocarriers forms the basis of innovative targeting techniques. After being conjugated with the treatment method, ligands for targeting hepatocellular carcinoma cells included asialoglycoprotein, galactoside, lactobionic acid, mannose-6-phosphate, PDGF, antibodies, and aptamers.
科研通智能强力驱动
Strongly Powered by AbleSci AI